37901-90-9 Usage
General Description
2-Nitro-3-Amino-4-Methylbenzoic Acid is a specific type of chemical compound. It falls under the category of aromatic benzoic acids which are characterized by a benzene ring bonded to a carboxylic acid. It possesses nitro, amino, and methyl functional groups. It is known for its yellow crystalline appearance. The chemical formula for this compound is C8H8N2O4, indicating that it is composed of eight carbon atoms, eight hydrogen atoms, two nitrogen atoms, and four oxygen atoms. It is typically used as an intermediate in the production of other chemicals in various industries. Like many other benzoic acids, it is essential to handle this chemical with care due to its potential for causing harm to skin and eyes.
Check Digit Verification of cas no
The CAS Registry Mumber 37901-90-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,7,9,0 and 1 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 37901-90:
(7*3)+(6*7)+(5*9)+(4*0)+(3*1)+(2*9)+(1*0)=129
129 % 10 = 9
So 37901-90-9 is a valid CAS Registry Number.
InChI:InChI=1/C8H8N2O4/c1-4-2-3-5(8(11)12)7(6(4)9)10(13)14/h2-3H,9H2,1H3,(H,11,12)
37901-90-9Relevant articles and documents
COVALENT INHIBITORS OF KRAS
-
, (2018/12/13)
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, R2a,
NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE
-
Page/Page column 71, (2008/06/13)
The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have Formula (I) wherein R1 is Formula (II), (III) or (IV) and A1, A2, A3, A4, X, Z, Z', R1, R2, R3, R4, R5 and R6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.
